Hemedex, Inc was founded in 2000 to commercialize a proprietary platform technology conceived at the Massachusetts Institute of Technology (MIT) to quantify tissue perfusion (i.e blood flow at the capillary level). This technology addresses the need for real-time, prognostic data in complex medical and surgical procedures. Their patented technology can provide an early warning of impending tissue ischemia.